Source: CVR Medical Corp.
  • CVR Medical (CVM) has closed the first tranche of a non-brokered private placement for gross proceeds of $115,000
  • The first tranche consisted of 3,850,000 units priced at $0.03 per unit
  • The offering, a necessary step in relaunching operations under new leadership, may be closed in additional tranches
  • CVR Medical is a healthcare company that operates in the medical device industry focused on the commercialization of its proprietary CSS, a device designed to detect and measure carotid arterial stenosis
  • CVR Medical Corp. (CVM) is down 14.29 per cent on the day, trading at C$0.03 per share at 4 pm EST

CVR Medical (CVM) has closed the first tranche of a non-brokered private placement for gross proceeds of $115,000.

The first tranche consisted of 3,850,000 units priced at $0.03 per unit. Each unit consists of one common share and one transferable common share purchase warrant. Warrants are exercisable to acquire an additional common share for $0.12 per share.

The proceeds from the offering will be used to cover the costs of the Annual General Meeting and filings fees.

Completion of the offering is a necessary step in relaunching operations under new leadership, with the ultimate goal of commercializing the Carotid Stenotic Scan device.

The common shares and warrants will be subject to a hold period expiring April 24, 2022.

The offering may be closed in additional tranches.

CVR Medical Corp. is a healthcare company that operates in the medical device industry focused on the commercialization of its proprietary Carotid Stenotic Scan device (CSS). The CSS is a patented device designed to detect and measure carotid arterial stenosis.

CVR Medical Corp. (CVM) is down 14.29 per cent on the day, trading at C$0.03 per share at 4 pm EST.

More From The Market Online

Reliq Health expands contract with U.S. health group

Reliq Health Technologies (TSXV:RHT) reveals it has expanded an existing contract with a large U.S. health group.

Telo Genomics and Emery Pharma collaborate

Telo Genomics (TSXV:TELO) collaborates with Emery Pharma to enhance cellular and molecular bioanalytical solutions for clinical research.

UniDoc brings AI to ER patients

UniDoc (CSE:UDOC) expands its AI partnership with DocBox, further integrating predictive analytics into emergency room operations.